Skip to main content

Novartis Campus opening further

Novartis Pavillon
| News

Novartis Campus opening further


Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel Area is the first major external organization to already have offices on the Novartis Campus.

Novartis Pavillon

The biotech and pharma group Novartis has announced that they are opening their campus further for the public. In a first phase, starting this year, Novartis opens the premises for startups, incubators, institutes, companies and partners. With this step, the company wants to strengthen collaboration between leading and emerging players in the fields of research, development and technology.

The first partner already on the campus is the Switzerland Innovation Park Basel Area that operates offices on the campus. Opened in mid-2020, the site of Switzerland Innovation Park Basel Area, which is run by Basel Area Business & Innovation, supports startups and established companies from the fields of digital health and personalized medicine. The objective is to establish a closeness between startups and the scientists from Novartis.

The second step will start late in 2022, when the Novartis Campus will be opened to the public during working hours. The Novartis Pavilion, which is currently under construction, will be a first visible milestone for the opening.

“By inviting the public to engage in dialogue in the Novartis Pavillon, we are strengthening our commitment and interaction with society as a whole and especially with the local community. We want to create transparency by encouraging exchanges and learning from each other,” said Jörg Reinhardt, Chairman of the Board of Directors. Novartis is confident the Campus opening will boost Basel as a business location and Switzerland in general.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.